Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus
- PMID: 3298936
- DOI: 10.1016/0026-0495(87)90153-3
Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus
Abstract
The effect of highly purified natural porcine GIP on C-peptide release was examined in six type I (insulin-dependent) diabetics (IDD) with residual beta-cell function, six type II non-insulin-dependent) diabetics (NIDD), and six normal subjects. All subjects were normal weight. From -120 minutes to 180 minutes glucose or insulin was infused IV to achieve a constant plasma glucose level of 8 mmol/L. On two separate days GIP (2 pmol/kg/min) or isotonic NaCl at random were infused from 0 to 30 minutes. After 10 minutes of GIP infusion plasma IR-GIP concentrations were in the physiologic postprandial range. At 30 minutes a further increase in IR-GIP to supraphysiologic levels occurred. In all subjects plasma, C-peptide increased more after 10 minutes of GIP infusion (IDD, 0.48 +/- 0.05; NIDD, 0.79 +/- 0.11; normal subjects, 2.27 +/- 0.29 nmol/L) than on the corresponding day with NaCl infusion (IDD, 0.35 +/- 0.03; NIDD, 0.62 +/- 0.08; normal subjects, 1.22 +/- 0.13 nmol/L, P less than .05 for all). The responses of the diabetics were significantly lower than that of the normal subjects (P less than .001 for both groups). No further increase in C-peptide occurred during the remaining 20 minutes of the GIP infusion in the diabetic subjects (IDD, 0.49 +/- 0.05; NIDD, 0.83 +/- 0.10 nmol/L). In the presence of a plasma glucose concentration of 8 mmol/L, physiologic concentrations of porcine GIP caused an immediate but impaired beta-cell response in IDD and NIDD patients.
Similar articles
-
A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.Diabetes Res Clin Pract. 1989 Nov 6;7(4):263-9. doi: 10.1016/0168-8227(89)90014-4. Diabetes Res Clin Pract. 1989. PMID: 2693029 Clinical Trial.
-
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903. doi: 10.1210/jc.2003-030738. J Clin Endocrinol Metab. 2003. PMID: 14557471 Clinical Trial.
-
Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent) diabetes mellitus.J Clin Endocrinol Metab. 1985 Jan;60(1):120-5. doi: 10.1210/jcem-60-1-120. J Clin Endocrinol Metab. 1985. PMID: 3880559
-
Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.Dan Med J. 2016 Apr;63(4):B5230. Dan Med J. 2016. PMID: 27034187 Review.
-
Conflicting gastric inhibitory polypeptide data: possible causes.Diabetes Res Clin Pract. 1993 Feb;19(2):93-101. doi: 10.1016/0168-8227(93)90102-b. Diabetes Res Clin Pract. 1993. PMID: 8472632 Review.
Cited by
-
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.Diabetes. 2009 Jun;58(6):1342-9. doi: 10.2337/db08-0958. Epub 2009 Mar 10. Diabetes. 2009. PMID: 19276444 Free PMC article. Clinical Trial.
-
Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches.Biology (Basel). 2020 Dec 16;9(12):473. doi: 10.3390/biology9120473. Biology (Basel). 2020. PMID: 33339298 Free PMC article. Review.
-
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.Physiology (Bethesda). 2024 May 1;39(3):142-156. doi: 10.1152/physiol.00032.2023. Epub 2024 Feb 14. Physiology (Bethesda). 2024. PMID: 38353610 Free PMC article. Review.
-
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.Endocr Rev. 2008 May;29(3):367-79. doi: 10.1210/er.2007-0031. Epub 2008 Feb 21. Endocr Rev. 2008. PMID: 18292465 Free PMC article. Review.
-
Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.Diabetologia. 2007 Apr;50(4):806-13. doi: 10.1007/s00125-007-0598-z. Epub 2007 Feb 16. Diabetologia. 2007. PMID: 17334652
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical